IL6 and Hyperglycemia: Hyperglycemia triggers podocytes, mesangial cells, and tubule cells to release IL-6, contributing to systemic and localized subclinical inflammation, and the use of SGLT-2i has been demonstrated to reduce IL-6 levels [88].